FindTrial
Sign In

NeuroPET GBG 001 - Mapping pathogenic processes associated with the development of neurodegenerative disorders using novel neuroimaging modalities

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-513499-16-00
Enrollment
300
Registered
2024-10-08
Start date
2024-10-08
Completion date
Unknown
Last updated
2024-10-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neurodegenerative diseases

Brief summary

Standardized uptake value ratios of [18]F-R0948 in selected cortical brain regions (normalized to a reference region).

Detailed description

CSF measures of sAPPalpha, sAPPbeta, A􀀈38, A􀀈40, A􀀈42, p-tau181, ptau231, total (t-) tau, neurofilament light (NFL), H-FABP, ViliP-1, SNAP-25, dendritic protein neurogranin, CSF/serum albumin ratio, MBP, cytokines, YKL-40, SV2A, and chitotriosidase, Structural and functional measures derived from MRI (cortical volumes and thickness, BOL T signal in selected brain regions, white matter and vascular changes, changes in diffusion), Cognitive performance as assessed by neuropsychological testing, Plasma measures of A􀀈40, A􀀈42, NFL and p-tau

Interventions

DRUGRO948 (18F)
DRUGSahlgrenska

Sponsors

Vaestra Goetalandsregionen
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Standardized uptake value ratios of [18]F-R0948 in selected cortical brain regions (normalized to a reference region).—

Secondary

MeasureTime frame
CSF measures of sAPPalpha, sAPPbeta, A􀀈38, A􀀈40, A􀀈42, p-tau181, ptau231, total (t-) tau, neurofilament light (NFL), H-FABP, ViliP-1, SNAP-25, dendritic protein neurogranin, CSF/serum albumin ratio, MBP, cytokines, YKL-40, SV2A, and chitotriosidase, Structural and functional measures derived from MRI (cortical volumes and thickness, BOL T signal in selected brain regions, white matter and vascular changes, changes in diffusion), Cognitive performance as assessed by neuropsychological testing, Plasma measures of A􀀈40, A􀀈42, NFL and p-tau—

Countries

Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026